Prescription Drug Reform Gains Momentum: What the New Senate Bill Means for Plan Sponsors

ProCare Rx Team • April 15, 2025

Prescription Drug Reform Gains Momentum: What the New Senate Bill Means for Plan Sponsors

The Senate Judiciary Committee has unanimously advanced the Prescription Pricing for the People Act of 2025. The voice vote signals rare bipartisan agreement on a complex issue: prescription drug pricing and the role of pharmacy benefit managers (PBMs) in driving those costs.

The legislation, if passed, would require the Federal Trade Commission (FTC) to further investigate the practices of intermediaries in the pharmaceutical supply chain—and recommend policies that promote transparency and fair competition. It’s a move that reflects growing concern about market consolidation, limited pricing visibility, and the potential impact on patients and payers alike.

It’s also a step toward giving plan sponsors the information they need to make better decisions. And that’s something we believe in deeply.


What’s in the Prescription Pricing for the People Act of 2025?

The bill, introduced by Senator Chuck Grassley (R-IA), directs the FTC to examine how PBMs influence drug pricing, reimbursement, and patient access. Specifically, it calls for a study of:

  • PBM pricing and spread practices
    Investigating whether PBMs are reimbursing pharmacies less than they charge plan sponsors.
  • Patient steering to owned pharmacies
    Determining whether PBMs direct patients toward affiliated pharmacies, limiting choice and impacting independents.
  • Use of competitive pharmacy data
    Exploring how PBMs may use claims data from unaffiliated pharmacies to gain a market edge.
  • Formulary design and cost structure
    Looking at whether PBMs design formularies in ways that favor higher-cost drugs when lower-cost options are available.

The FTC would be required to submit an interim report within 180 days of enactment and a final report within one year—both with recommendations for legislative or regulatory action.

Why It Matters

This legislation comes amid broader concerns over how opaque pricing and consolidation in the pharmacy supply chain affect employers, health plans, and patients. As Congress takes a closer look, plan sponsors are being asked to do the same—evaluating whether their PBM relationships are really delivering on value, access, and cost control.

The push for oversight is less about political positioning and more about rebalancing the system. Right now, too many decision-making levers are hidden from the people actually footing the bill.


Supporting Plan Sponsor Control

While transparency is essential, it’s only part of the equation. At ProCare Rx, we believe that plan sponsors deserve more than visibility—they deserve control.

That means:

  • Contracts with clear terms and no surprise fees
  • Access to real-time data for smarter, faster decisions
  • The ability to customize benefit design, rather than accept a one-size-fits-all model
  • A pharmacy benefit partner that answers to you, not to shareholders or owned pharmacies

This is one of our Seven Pillars for a reason: when employers have more control, they can manage their risk more effectively, protect their members more thoughtfully, and ensure that pharmacy benefits remain sustainable long-term.


Looking Ahead

As the Prescription Pricing for the People Act of 2025 continues to move forward, we see an opportunity to bring greater balance to the pharmacy benefit landscape—one where decisions are driven by value, not volume.

For plan sponsors and the patients they serve, that’s a win.

We’ll continue to follow this legislation closely and share updates as they become available.


About ProCare Rx
ProCare Rx is a privately held, independent pharmacy benefit manager (PBM) that has empowered healthcare and self-insured organizations since 1988. We provide fully integrated, in-house solutions—including claims adjudication, clinical program design, pharmacy network access, cost containment, and data analytics—all supported in the U.S. Our flexible, transparent model serves self-insured employers, third-party administrators (TPA), brokers, health plans, health systems, managed care organizations (MCO), unions, workers’ compensation programs, Medicare, Medicaid, hospices, and other PBMs. With a proprietary technology platform, commitment to ethical operations, and a focus on lowest net cost, ProCare Rx delivers long-term value, clinical performance, and trusted pharmacy benefit partnerships.

Media Contact:
Marc Cohen, VP, Marketing and Sales
marketing@ProCareRx.com

By ProCare Rx Team October 1, 2025
Drug costs continue to surge, regulatory winds are shifting, and employers are bracing for steeper expenses ahead. Now more than ever, your choice of PBM partner can be a major differentiator or a liability. Why This Moment Matters Cost growth expectations are steep. Employers are forecasting higher health care costs in 2026, with pharmacy spend as a central contributor. Some projections suggest pharmacy alone may rise by double digits next year, far outpacing general medical cost trends. Reform pressure is building. PBM practices are under increasing scrutiny. Policymakers, physician groups, and pharmacy organizations are pushing for reforms that would delink PBM profits from drug list prices, increase transparency, and ensure savings flow to plan sponsors and patients. PBMs themselves are already floating proposals to adjust their practices ahead of possible legislation. Regulation is becoming inconsistent and complex. While federal courts and Congress weigh in, states continue to pass new PBM laws. For multi-state employers, this means navigating a patchwork of rules that can be confusing, sometimes conflicting, and potentially at odds with fiduciary obligations. What to Look for in a PBM Partner Given this evolving landscape, employers should place extra emphasis on: Regulatory agility and compliance support Your PBM must help you navigate both federal and state-level requirements, protecting your plan against compliance risk. True cost transparency and incentive alignment Demand clarity on how your PBM is compensated. Incentives should be aligned with your plan, not tied to higher drug list prices or opaque rebate arrangements. Formulary integrity and clinical governance With expensive therapies hitting the market, your PBM should balance cost savings with clinical appropriateness, ensuring members receive the right drug, not just the cheapest option. Benefit design flexibility Rising costs require innovative plan designs such as specialty carve-outs, differential cost-sharing, or utilization management. Your PBM should be a partner in shaping these strategies, not a barrier. Member experience and adoption tools With members facing higher cost-sharing and more complex therapies, digital tools, adherence programs, and proactive engagement are essential for better outcomes. Proven performance and benchmarking In this climate, results matter. Your PBM should demonstrate measurable cost savings and clinical outcomes year over year, benchmarked against peers. The Bottom Line  Plan sponsors are entering a pivotal moment. The forces shaping pharmacy benefits include cost escalation, regulatory change, and clinical complexity. The status quo will not be enough. Choosing a PBM partner with regulatory foresight, aligned incentives, clinical integrity, and member-centric tools can help employers navigate this era, mitigate risk, and deliver sustainable value to their workforce. Sources Reuters – Pharma middlemen propose regulatory changes to avoid Trump administration rules Pharmacy Times – Pharmacy policy updates for September 2025 Bloomberg Law – Drug benefit compliance is a state-by-state test for sponsors NASPA – Over 100 pharmacy organizations urge PBM reform AMA – Advocacy update spotlight on PBMs Healthcare Dive – Employers expect 9% higher health costs in 2026 WorldatWork – Business Group on Health predicts 9% higher healthcare costs in 2026 PwC – Behind the numbers: Rising drug spend ProCare Rx PBM 101 video script
By ProCare Rx September 29, 2025
The world of pharma is evolving quickly, with direct-to-consumer (DTC) marketing and new patient engagement strategies changing how therapies are launched, prescribed, and accessed. Join John Drakulich for an insightful conversation on The New Pharma Playbook and what these shifts mean for employers, health plans, pharmacies, and patients. Hosted by ProCare Rx , this webinar takes a closer look at how DTC marketing influences prescribing behavior, patient decision-making, and overall drug costs, and how transparent PBM strategies can help plan sponsors navigate these challenges while prioritizing member care. Attendees will walk away with practical insights into how PBMs like ProCare Rx are driving innovation, improving access, and keeping costs under control in a changing marketplace.
By ProCare Rx Team September 5, 2025
PBM 101, Part 1: Why PBMs Matter for Employers
By ProCare Rx Team August 28, 2025
ProCare Rx appoints Marco Torelli as new SVP of Labor and Public Sector
By ProCare Rx Team August 27, 2025
ProCare Rx Names JD Edwards Senior Vice President of Sales
By ProCare Rx Team August 18, 2025
This appointment brings together multiple parts of the business under one umbrella to best serve our PBM clients and members, assuring that ClearSight transparency and Lowest Net Cost remains at the forefront of the innovative organization.
By ProCare Rx Team August 5, 2025
When Courts and Care Collide: What the Arkansas PBM Ruling Means for the Industry
By ProCare Rx Team July 8, 2025
Prescription Drug Pricing: Will Policy Fix What Patients Feel?
By ProCare Rx Team June 2, 2025
Is Your PBM Working for You…Or Against You? How to Ask the Right Questions and Spot Red Flags in Pharmacy Benefit Management
By ProCare Rx May 20, 2025
ProCare Rx Announces New Executive Appointment and Launch of Technology Division to Drive Innovation and Growth The newly created role is expected to solidify leadership of the core technology infrastructure to both enhance support for current clients as well as developing additional value-added offerings to the marketplace.